FDA Received More User-Fee Paying Applications In FY 2004 Than Expected
This article was originally published in The Pink Sheet Daily
Executive Summary
With a “greater than anticipated” number of fee-paying applications received by FDA, the agency collected $5 mil. more than projected at the beginning of the year, the FY 2004 PDUFA Financial Report states.
You may also be interested in...
New Molecular Entity Submissions Increase In FY 2004
FDA receives 28 NME filings in fiscal year 2004, marking the third year of growth. However, NME submissions have not climbed back up to the 1999-2001 level. BLA submissions spike in 2004 with 20 filings, up from eight the year before.
FDA User Fee Rates Will Increase 17% For Fiscal Year 2005
Applications including clinical data will cost $672,000. Applications without clinical data and supplemental applications with clinical data will cost $336,000.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.